Dec 5, 2012 | Recent Deals | Silicon Valley
O’Melveny & Myers LLP represented Alta Partners, a leading venture capital firm in life sciences, as lead investor in Zafgen, Inc.’s US$21 million Series D equity financing. Zafgen, Inc. is a biopharmaceutical company dedicated to addressing the needs of severely obese patients. Alta Partners joins existing investors Atlas Venture and Third Rock Ventures. Proceeds from the financing will be used for the development of beloranib, an obesity therapeutic in phase 2a clinical development.
The Silicon Valley-based team was led by partner Sam Zucker and counsel Jeff Cislini.
Related Posts:
- O’Melveny Represents Lookout in US$55 Million Strategic Financing Round
- O’Melveny Represents Investors in US$40 Million Series A Convertible Preferred Stock Financing with Alimera Sciences
- O’Melveny Represents Rizvi Traverse Management as Lead Investor in Flipboard’s Financing Round
- O’Melveny Represents Cytomx Therapeutics in Expansion of Series B Financing
- O’Melveny Represents Progenics Pharmaceuticals in Proposed Public Offering
